The company said, “As previously announced, Equillium (EQ) had no further intention to continue development of itolizumab, therefore on September 30, 2025, Biocon and Equillium entered into an agreement to terminate their collaboration and license agreement and other agreements relating to itolizumab.”
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EQ:
- Equillium Files Prospectus for $75 Million Stock Sale
- Equillium files to sell 52.63M shares of common stock for holders
- Equillium Regains Nasdaq Compliance with Bid Price Rule
- Equillium price target lowered to $4 from $8 at Jefferies
- Equillium’s Strategic Moves and Financial Position Lead to Hold Rating Amid Clinical Trial Uncertainties